# US 5,700,638 A · Cell death regulator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,700,638 A
- Document ID: US5700638A
- Status: Granted
- Kind: A
- Application number: 08/248,819
- Filed: 1994-05-25
- Granted: 1997-12-23
- Earliest claimed: 1993-08-26
- Assignees: Washington University
- Inventors: Stanley J. Korsmeyer
- Web page: https://patentgrep.com/patent/US5700638A

## CPC

- C07K 14/82: Translation products from oncogenes
- A61P 35/00: Antineoplastic agents
- C07K 14/4747: {Apoptosis related proteins}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- Y10S 435/81: Packaged device or kit
- Y10S 530/827: Proteins from mammals or birds
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention provides a bcl-2 related protein, bcl-2 muteins, and uses thereof.

## Claims

### Claim 1

A method for producing a mutant bcl-2 protein that substantially lacks death repressor activity and/or substantially lacks binding to Bax, said method comprising the steps of;
expressing in a cell or translation reaction a polynucleotide encoding a mutant bcl-2 protein comprising a polypeptide sequence which is substantially identical to a naturally-occurring bcl-2 protein and which has an amino acid substitution or deletion in a BH1 or BH2 domain, whereby the mutant bcl-2 protein is substantially incapable of binding to Bax and/or is substantially incapable of death repressor activity.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the mutant bcl-2 protein has a polypeptide sequence of a naturally occurring human bcl-2 wherein at least one amino acid substitution or deletion is present in a BH1 domain consisting of amino acid positions 136-155 of SEQ ID No: 10 or a BH2 domain consisting of amino acid positions 187-202 of SEQ ID No: 10.

### Claim 3 (depends on 2)

A method according to claim 2, wherein the mutant bcl-2 protein comprises an amino acid substitution or deletion at an amino acid position selected from the group consisting of position 137, 138, 139, 140, 143, 144, 145, 187, 188, 189, 190, 191, 193, 194, 195, 196, and 199.

### Claim 4 (depends on 2)

A method according to claim 2, wherein the mutant bcl-2 protein comprises an amino acid substitution or deletion of at least one amino acid position of an FRDG motif (positions 137-140), an NWGR motif (positions 142-145), substitution or deletion of at least one amino acid position of an GWDA motif (positions 193-196), or substitution for tryptophan at position 188.

### Claim 5 (depends on 3)

A method of claim 3, wherein the amino acid substitution comprises a replacement amino acid which is selected from the group consisting of alanine, leucine, and glutamic acid.

### Claim 6 (depends on 1)

A method of claim 1, wherein the mutant bcl-2 protein has a BH1 domain, a BH2 domain, or a BH1 and BH2 domain joined in polypeptide linkage.

### Claim 7 (depends on 6)

A method of claim 6, wherein the BH1 and BH2 domain joined in polypeptide linkage comprises amino acid positions 136-202 of SEQ ID NO:10.

### Claim 8

A method of identifying candidate bcl-2-modulating agents, comprising:
performing a heterodimerization assay which includes a bcl-2 polypeptide comprising a BH1 and/or BH2 domain with a Bax polypeptide and an agent;
determining whether the agent inhibits heterodimerization of the bcl-2 polypeptide to the Bax polypeptide;
identifying agents which inhibit said heterodimerization as candidate bcl-2 modulating agents which inhibit death repressor activity of bcl-2.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the bcl-2 polypeptide is a full-length bcl-2 protein comprising a polypeptide sequence at positions 136-155 consisting of --ELFRDGVNWGRIVAFFEFGG-- of SEQ ID NO: 10 and which binds to a full-length Bax protein.

### Claim 10 (depends on 8)

A method according to claim 8, wherein the bcl-2 polypeptide is a full-length bcl-2 protein comprising a polypeptide sequence at positions 187-202 consisting of --TWIQDNGGWDAFVELY-- of SEQ ID NO: 1 and which binds to a full-length Bax protein.

### Claim 11

A mutant bcl-2 polypeptide comprising an amino acid substitution or deletion in a BH-1 or BH-2 domain, wherein amino acid substitution or deletion is in an amino acid postion corresponding to amino acid residues 136-155 or 187-202 of SEQ ID NO:10, as aligned in FIG. 22(a-c), whereby the mutant bcl-2 protein is substantially incapable of binding to Bax and/or is substantially incapable of death repressor activity.

### Claim 12 (depends on 11)

A mutant bcl-2 polypeptide of claim 11, wherein the mutant bcl-2 protein has a polypeptide sequence of a naturally-occurring human bcl-2 protein wherein at least one amino acid substitution or deletion is present in a BH1 domain consisting of amino acid positions 136-155 (--ELFRDGVNWGRIVAFFEFGG-- of SEQ ID NO:10 or a BH2 domain consisting of amino acid positions 187-202 (--TWIQDNGGWDAFVELY-- of SEQ ID NO:10.

### Claim 13 (depends on 12)

A mutant bcl-2 polypeptide of claim 12, wherein the mutant bcl-2 protein comprises an amino acid substitution or deletion at an amino acid position selected from the group consisting of position 137, 138, 139, 140, 143, 144, 145, 187, 188, 189, 190, 191, 193, 194, 195, 196, and 199.

### Claim 14 (depends on 13)

A mutant bcl-2 polypeptide of claim 13, wherein the mutant bcl-2 protein comprises an amino acid substitution or delletion of at least one amino acid position of an FRDG motif (positions 137-140), an NWGR motif (positions 142-145), or an GWDA motif (positions 193-196).

### Claim 15 (depends on 14)

A mutant bcl-2 polypeptide of claim 14, wherein the amino acid substitution comprises a replacement amino acid which is selected from the group consisting of alanine, leucine, and glutamic acid.

### Claim 16 (depends on 15)

A mutant bcl-2 polypeptide of claim 15, wherein the mutant bcl-2 protein a BH1 domain, a BH2 domain, or a BH1 and BH2 domain joined in polypeptide linkage.

### Claim 17 (depends on 11)

A mutant bcl-2 polypeptide of claim 11, wherein the BH1 and BH2 domain joined in polypeptide linkage comprise amino acids corresponding to positions 136-202 of SEQ ID NO: 10.

### Claim 18

A method for inhibiting the cell death repressor activity of bcl-2, said method comprising the steps of:
introducing a mutation into a bcl-2 polynucleotide encoding a bcl-2 polypeptide to produce a mutated bcl-2 polynucleotide, whereby said mutated bcl-2 polynucleotide encodes a mutant bcl-2 polypeptide comprising an amino acid substitution or deletion in a BH1 or BH2 domain, and wherein said mutant bcl-2 polypeptide substantially lacks binding to Bax and/or substantially lacks death repressor activity.

### Claim 19

A method for identifying a mutant bcl-2 comprising an amino acid substitution or deletion at an amino acid position of a BH1 or BH2 domain, said method comprising obtaining a sample containing a bcl-2 protein and detecting whether the bcl-2 protein has a substitution at a position in a BH1 or BH2 domain relative to naturally-occurring bcl-2 protein.

### Claim 20 (depends on 19)

A method of claim 19, wherein the step of detecting is performed by detecting whether the bcl-2 protein is capable of binding Bax under suitable aqueous binding conditions.

### Claim 21

A method for identifying mutant bcl-2 proteins which substantially lack binding to Bax and/or substantially lack death repressor activity, said method comprising the steps of:
introducing a mutation into a bcl-2 polynucleotide encoding a bcl-2 polypeptide to produce a mutated bcl-2 polynucleotide, whereby said mutated bcl-2 polynucleotide encodes a mutant bcl-2 polypeptide comprising an amino acid substitution or deletion in a BH1 or BH2 domain;
expressing said mutant bcl-2 polypeptide in a mammalian cell which expresses Bax and which is capable of undergoing bcl-2-sensitive apoptosis;
determining whether expression of the mutant bcl-2 polypeptide inhibits death repressor activity of a bcl-2 protein endogenous to said mammalian cell and/or whether said mutant bcl-2 protein itself lacks death repressor activity and/or are incapable of providing inhibition of said bcl-2-sensitive apoptosis; and
identifying mutant bcl-2 proteins which inhibit endogenous bcl-2 death repressor activity and/or which are incapable of providing inhibition of said bcl-2-sensitive apoptosis as being bcl-2 proteins which lack binding to Bax and/or substantially lack death repressor activity.